Challenges in understanding host genetics and severity of community-acquired pneumonia

Jordi Solé-Violán, Elisa Hernández-Brito, José Manuel Valencia, Estefanía Herrera-Ramos, Luis Borderías, M. Luisa Briones, Olga Rajas, Jorge Freixinet, Leonardo Lorente, Antoni Payeras, Jose Ferreres, Nieves Carbonell, Nereida González-Quevedo, Jesús M. González-Martín, Felipe Rodríguez de Castro, Carlos Rodríguez-Gallego

RESEARCH LETTER

Title: CHALLENGES IN UNDERSTANDING HOST GENETICS AND SEVERITY OF COMMUNITY-ACQUIRED PNEUMONIA.

Full names

Jordi Solé-Violán,[1,2,#] Elisa Hernández-Brito,[3,4,#] José Manuel Valencia,[5] Estefanía Herrera-Ramos,[4] Luis Borderías,[6] M. Luisa Briones[7], Olga Rajas[8], Jorge Freixinet[9], Leonardo Lorente,[10] Antoni Payeras[11], Jose Ferreres[12], Nieves Carbonell[12] Nereida González-Quevedo[3], Jesús M. González-Martín[13], Felipe Rodríguez de Castro[4,5], Carlos Rodríguez-Gallego[3,14*]

Address

[1]Intensive Care Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.

[2] CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.

[3]Department of Immunology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.

[4]Department of Medical and Surgical Sciences, School of Medicine, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.

[5]Department of Respiratory Diseases, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.

[6]Department of Respiratory Diseases, Hospital San Jorge, Huesca, Spain.

[7]Department of Respiratory Diseases, Hospital Clínico y Universitario de Valencia, Valencia, Spain.

[8]Department of Respiratory Diseases, Hospital Universitario de la Princesa, Madrid, Spain.

[9]Department of Thoracic Surgery, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.

[10]Intensive Care Unit, Hospital Universitario de Canarias, La Laguna, Spain.

[11]Department of Internal Medicine, Hospital Son Llatzer, Palma de Mallorca, Spain.

[12]Intensive Care Unit, Hospital Clínico y Universitario de Valencia, Valencia, Spain.

[13]Biostatistics Division, Research Unit, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain

[14]University Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain.

[#]These authors contributed equally to this work.

Take home message

We did not find an association of two top-associated *FER* variants with severity of community-acquired pneumonia. A precise characterization of phenotypes may be required in order to unravel the genetic mechanisms predisposing to poor outcome in sepsis.

*Author for correspondence

Carlos Rodríguez-Gallego

jrodgal@gobiernodecanarias.org

To the Editor:

A heritable predisposition to early death due to infection was observed three decades ago [1]. Apart from exciting discoveries in the field of primary immunodeficiencies, genetic variants predisposing to severe infection and outcome at a population level remains largely elusive [2,3]. Genetic association studies on sepsis were largely based on a candidate gene approach. In 2015, Rautanen et al [4] reported the first Genome wide association study (GWAS) in sepsis. A meta-analysis of three independent cohorts of critically-ill patients with sepsis recruited in numerous centers from Europe, Canada, USA, Australia, New Zeeland and South Africa was performed. They reported that the C allele of the single nucleotide variant (SNV) rs4957796 at the *FER* gene was associated, with a protective additive effect, in 28-day survival only when patients with pneumonia, but not those with other causes of sepsis, were considered. Schöneweck et al [5] did not replicate Rautanen´s findings in a mixed cohort of patients of European ancestry with severe sepsis admitted at German ICUs. However, their study was underpowered for mortality. Hinz et al [6], in a cohort of Caucasian patients with ARDS due to pneumonia from a single Centre in Germany, found that the rs4957796 TT genotype was associated with a higher 90-day mortality exclusively in the small subgroup of patients with severe ARDS.

We prospectively explored, in a large cohort of ethnically homogeneous patients hospitalized with community-acquired pneumonia (CAP), the potential role of the two-top associated SNV in the *FER* gene (rs4957796 and rs62375529) [4] in outcome.

Between March 2001 and December 2014, we recruited 1398 patients with CAP at six institutions in Spain. Foreigners and individuals with ancestors other than Spanish were previously excluded. DNA samples from 960 patients were available and

successfully analyzed for the rs4957796 and rs62375529 SNV. CAP, severe sepsis, septic shock, and acute respiratory distress syndrome (ARDS) were diagnosed as previously reported [7-9]. Empirical antibiotic therapy was appropriate according to American Thoracic Society/Infectious Diseases Society of America guidelines in 87% of the patients. Patients were observed for 90 days after hospital discharge or death. The control group consisted of 996 unrelated healthy volunteers and patients without a previous history of relevant infections of the same ethnicity as CAP patients. Genomic DNA was obtained as previously described [7-9]. Analyses of SNPs were performed by predesigned Taqman SNP genotyping assays (C__28002866_10 [rs4957796] and C__90533619_10 [rs62375529]) with commercially available reagents by means of ViiA™7 Real-time PCR System (Applied Biosystems, Foster City, CA, USA). Informed consent was obtained from the patients or their relatives. The protocol was approved by the local ethics committee of the six hospitals. All steps were performed in complete accordance to the Helsinki declaration.

Causative microorganisms were identified in 460 patients (47.9%), and 59% of the cases were due to *S. pneumoniae*. A total of 338 patients were admitted to the ICU; 64 developed ARDS, 108 severe sepsis and 214 septic shock. Bacteremia was observed in 119 patients (12.4%), 86 of them caused by *S. pneumoniae.*

Genotype distribution of both SNPs did not differ significantly under conditions of Hardy-Weinberg equilibrium in the control group. The allelic frequencies under analysis were not significantly different between patients with CAP and the control group (Table 1); no differences were either observed when only patients with pneumococcal CAP were considered (data not shown). When an additive logistic regression analysis was performed, the *FER* rs4957796 and rs62375529 SNV did not confer significant risk for

need of ICU admission, development of sepsis, severe sepsis/septic shock, ARDS, 28-day mortality, or 90-day mortality (Table 1). No associations were either found when the analysis of mortality was restricted to patients with sepsis or severe sepsis/septic shock (Table 1). At a significance level of 5% and 80% power, the relative risk to detect a significant allelic association of rs4957796 was 1.76, 1.44 and 1.82 for ARDS, severe sepsis/septic shock and 28-day mortality respectively. Conversely, the rs62375529 CC genotype was overrepresented in patients who developed severe sepsis/septic shock, and a weak association with 28-day mortality was also observed (Table 1). After adjustment for age, sex, comorbidities, and admitting hospital, the rs62375529 *FER* variant remains significantly associated with severe sepsis risk (OR=5.17; 95% CI 1.96-13.68, p=0.001). The association of the rs62375529 *FER* SNV with 28-day mortality would not remain significant after corrections for multiple testing. However, the association of the rs62375529 with development of severe sepsis/septic shock, would remain significant after correction for multiple comparisons (eight phenotype comparison for each allele). These results were surprising, since Rautanen et al found that the C allele of rs62375529 associated, with an additive effect, to a higher 28-day survival in their cohort of patients with pneumonia and severe sepsis [4].

Formal validation is essential to confirm findings observed in a GWAS. It usually requires large sample sizes; a homogeneous ethnic background, a precise phenotype definition and a clear identification of other involved risk factors [10,11]. Phenotype definitions may vary considerably across studies and may be a source of contradictory results [11]. The severity, as well as the immune and inflammatory response, in patients with pneumonia can be considered as a continuum of disease, ranging from CAP to the development of sepsis, septic shock, ARDS and multiple organ dysfunction syndrome. Therefore, there may be some overlap between CAP and CAP induced

sepsis, which could shadow the association between genotype and phenotype. Our cohort was composed of patients hospitalized with CAP with different degrees of disease severity. In contrast, the association reported by Rautanen and col [4], focused exclusively in ICU patients with pneumonia-associated sepsis. Although the majority of pneumonias were classified as CAP, the type of pneumonia was not specified in 24.7% of patients. We documented a causative organism in 47.9% of our patients (mainly *S. pneumoniae*). In Rautanen´s study between 49% and 63% of pulmonary infections were caused by Gram-positive, but the proportion of *S. pneumoniae* was not specified. These differences may be relevant because the inflammatory and immune response varies depending on the source of infection and the causative pathogen [11].

Our study may be underpowered to detect clinically relevant differences, particularly for mortality endpoint. In any case, our sample is sufficient to detect a relative risk for 28-day mortality of 1.82, 3.55 and 2.00 in the entirely population, and in the subgroups of patients with sepsis and severe sepsis/septic shock respectively, at a significance threshold of 0.05 with 80% power. However, our study is still underpowered to detect a effect on mortality in patients admitted to ICU.

Intriguingly, we found a directionally inconsistent association for the rs62375529 variant between our results and those of Rautanen et al [4]. Data from Schöneweck et al [5] was extracted from a GWAS [12] in which the 14 top associations at 12 loci from Rautanen et al [4] were compared. They found that only two of these variants were weakly associated with 28-day mortality. However, the alleles effect in both GWAS were also directionally inconsistent [12]. Associations of opposite alleles at the same biallelic locus with the same disease, usually referred as "flip-flop" associations, are confusing findings, particularly when they are observed in the same ethnic group [13, 14]. Flip-flop associations may result from heterogeneous effects of the same variant

due to differences in genetic background, environment or comorbidities. In addition, differences in linkage disequilibrium (LD) architectures or LD patterns between populations could also lead to flip-flop associations. Variation in LD architecture across different populations is common in populations of different ethnic origin, but it has been also observed among populations within the same ethnic group [13,14]. Larger heterozygosity in southern compared to northern Europe populations has been reported [15]. Noteworthy, the minor allele frequencies at the rs4957796 and rs62375529 SNVs are significantly lower in Southern European, particularly in Spanish, than in Northern European populations from the 1000 genomes project (http://phase3browser.1000genomes.org). Likewise, LD between both SNVs is also lower in Southern European than in Northern European populations (for instance, D' 0.78 in our control population versus 0.97 and 0.94 in the FIN and CEU populations from 1000 genomes project respectively). These differences between populations, and a different extent of LD of the rs4957796 SNV with a putative, or different, causal variants, might be the cause of the observed directionally inconsistent associations.

In an ethnically homogeneous population of patients with CAP, we could not confirm the protective effect of the rs4957796 C allele within the FER gene, but we found a directionally inconsistent association for the rs62375529 variant. Genetic variants may have a different impact depending on different populations, causative microorganism, source of infection and severity of disease.

Due to differences such as phenotype definition and sampling strategy, our study cannot be considered a formal replication of the results of the Rautanen study (4). In any case, we have not been able to reproduce these results in patients hospitalized with CAP, Our results emphasize the importance of replicating the results of GWAS, and illustrates

some of the bias that can occur as well as the challenges of translating the finding of *FER* variants as predictors of mortality into clinical practice. Further research is needed to better delineate the extent of the role of *FER* variants in sepsis severity. A more precisely characterization of sepsis phenotypes may be required in order to unravel the genetic mechanism predisposing to sepsis severity.

DECLARATION OF INTERESTS

The authors declare no conflict of interest.

REFERENCES

1. Sørensen TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988; 318: 727-732.

2. Casanova JL, Abel L. Human genetics of infectious diseases: Unique insights into immunological redundancy. Semin Immunol 2018; 36: 1-12.

3. Casanova JL. Human genetic basis of interindividual variability in the course of infection. Proc Natl Acad Sci USA 2015; 112: 7118-27.

4. Rautanen A, Mills TC, Gordon AC, Hutton P, Steffens M, Nuamah R, Chiche JD, Parks T, Chapman SJ, Davenport EE, Elliott KS, Bion J, Lichtner P, Meitinger T, Wienker TF, Caulfield MJ, Mein C, Bloos F, Bobek I, Cotogni P, Sramek V, Sarapuu S, Kobilay M, Ranieri VM, Rello J, Sirgo G, Weiss YG, Russwurm S, Schneider EM, Reinhart K, Holloway PA, Knight JC, Garrard CS, Russell JA, Walley KR, Stüber F, Hill AV, Hinds CJ; ESICM/ECCRN GenOSept Investigators. Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Respir Med 2015; 3: 53-60.

5. Schöneweck F, Kuhnt E, Scholz M, Brunkhorst FM, Scherag A. Common genomic variation in the FER gene: useful to stratify patients with sepsis due to pneumonia? Intensive Care Med 2015; 41: 1379-81.

6. Hinz J, Büttner B, Kriesel F, Steinau M, Frederik Popov A, Ghadimi M, Beissbarth T, Tzvetkov M, Bergmann I, Mansur A. The FER rs4957796 TT genotype is associated with unfavorable 90-day survival in Caucasian patients with severe ARDS due to pneumonia. Sci Rep 2017; 7: 9887.

7. Solé-Violán J, García-Laorden MI, Marcos-Ramos JA, de Castro FR, Rajas O, Borderías L Briones ML, Herrera-Ramos E, Blanquer J, Aspa J, Florido Y, García-Bello MA, Ferrer-Agüero JM, Sologuren I, Rodriguez-Gallego C. The Fcγ receptor IIA-H/H131 genotype is associated with bacteremia in pneumococcal community-acquired pneumonia. Crit Care Med 2011; 39: 1388-93.

8. Martín-Loeches I, Solé-Violán J, Rodríguez de Castro F, García-Laorden MI, Borderías L, Blanquer J, Rajas O, Briones ML, Aspa J, Herrera-Ramos E, Marcos-Ramos JA, Sologuren I, González-Quevedo N, Ferrer-Agüero JM, Noda J, Rodríguez-Gallego C. Variants at the promoter of the interleukin-6 gene are associated with severity and outcome of pneumococcal community-acquired pneumonia. Intensive Care Med 2012; 38: 256-62.

9. García-Laorden MI, Rodríguez de Castro F, Solé-Violán J, Payeras A, Briones ML, Borderías L, Aspa J, Blanquer J, Rajas O, Marcos-Ramos JA, Herrera-Ramos E, García-Bello MA, Noda J, Ferrer JM, Rello J, Rodríguez-Gallego C. The role of mannose-binding lectin in pneumococcal infection. Eur Respir J 2013; 41: 131-9.

10. König IR. Validation in Genetic Association Studies. Brief Bioinform 2011; 12: 253-258.

11. Goh C, Knight JC.Enhanced understanding of the host-pathogen interaction in sepsis: new opportunities for omic approaches. Lancet Respir Med 2017; 5: 212-223.

12. Scherag A, Schöneweck F, Kesselmeier M, Taudien S, Platzer M, Felder M, Sponholz C, Rautanen A, Hill AVS, Hinds CJ, Hossain H, Suttorp N, Kurzai O,

Slevogt H, Giamarellos-Bourboulis EJ, Armaganidis A, Trips E, Scholz M, Brunkhorst FM. Genetic Factors of the Disease Course after Sepsis: A Genome-Wide Study for 28 Day Mortality. EBioMedicine 2016; 12: 239-246.

13. Lin PI, Vance JM, Pericak-Vance MA, Martin ER. No gene is an island: the flip-flop phenomenon. Am J Hum Genet 2007; 80 :531-538.

14. Clarke GM, Cardon LR. Aspects of observing and claiming allele flips in association studies. Genet Epidemiol 2010; 34: 266-274.

15. Taudien S, Lausser L, Giamarellos-Bourboulis EJ, Sponholz C, Schöneweck F, Felder M, Schirra LR, Schmid F, Gogos C, Groth S, Petersen BS, Franke A, Lieb W, Huse K, Zipfel PF, Kurzai O, Moepps B, Gierschik P, Bauer M, Scherag A, Kestler HA, Platzer M. Genetic Factors of the Disease Course After Sepsis: Rare Deleterious Variants Are Predictive. EBioMedicine 2016; 12: 227-238. erg equilibrium in the control group (p= 0.444 for rs4957796, p=0.746 for rs62375529).

Table 1. Genotype data of patients with community-acquired pneumonia

					Statistical significance		
					p **OR (95% CI)** Genotype Comparisons	**p** **OR (95% CI)**	**p** **OR (95% CI)** Allele Comparisons
	N	**Genotype frequencies, N (%)**					
rs4957796		**CC**	**CT**	**TT**	**Recessive model: CC vs TC + TT**	**Adittive model**	
CAP	960	29 (52.7)	243 (46.8)	688 (49.8)	0.583	0.51 0.94 (0.80-1.12)	0.502 0.94 (0.80-1.12)
Control	996	26 (47.3)	276 (53.2)	694 (50.2)	1.16 (0.68-1.99)		
Dead 28 days	57	2 (6.9)	11 (4.5)	44 (6.4)	0.688	0.44 0.81 (0.47-1.40)	0.446 0.81 (0.46-1.41)
Alive 28 days	903	27 (93.1)	232 (95.5)	644 (93.6)	1.18 (0.27-5.09)		
Dead 90 days	76	2 (6.9)	15 (6.2)	59 (8.6)	1.000	0.26 0.76 (0.47-1.24)	0.262 0.75 (0.46-1.24)
Alive 90 days	884	27 (93.1)	228 (93.8)	629 (91.4)	0.86 (0.20-3.68)		
ARDS	64	3 (10.3)	15 (6.2)	46 (6.7)	0.435	0.82 1.06 (0.66-1.70)	0.814 1.06 (0.65-1.72)
No ARDS	896	26 (89.7)	228 (93.8)	642 (93.3)	1.65 (0.48-5.59)		
SS/SSh	313	14 (48.3)	79 (32.5)	220 (32.0)	0.068	0.25 1.16 (0.90-1.50)	0.235 1.17 (0.90-1.51)
No SS/SSh	647	15 (51.7)	164 (67.5)	468 (68.0)	1.97 (0.94-4.14)		
Sepsis	765	27 (93.1)	192 (79.0)	546 (79.4)	0.041	0.34 1.16 (0.85-1.58)	0.338 1.17 (0.85-1.60)
No sepsis	195	2 (6.9)	51 (21.0)	142 (20.6)	3.53 (0.83-15)		
ICU	338	9 (31.0)	82 (33.7)	247 (35.9)	0.633	0.44 0.90 (0.70-1.17)	0.432 0.90 (0.69-1.17)
No ICU	622	20 (69.0)	161 (66.3)	441 (64.1)	0.82 (0.37-1.83)		
ICU dead 28 d[*]	44	1 (11.1)	6 (7.3)	37 (15.0)	1.000	0.093 0.55 (0.26-1.16)	0.106 0.54 (0.25-1.15)
ICU alive 28 d[*]	294	8 (88.9)	76 (92.7)	210 (85.0)	0.81 (0.10-6.81)		
ICU dead 90 d[*]	62	1 (11.1)	10 (12.2)	51 (20.6)	1.000	0.068 0.57 (0.31-1.08)	0.076 0.57 (0.30-1.07)
ICU alive 90 d[*]	276	8 (88.9)	72 (87.8)	196 (79.4)	0.55 (0.07-4.47)		
rs62375529		**CC**	**CT**	**TT**	**Recessive model: CC vs TC + TT**	**Adittive model**	
CAP	960	23 (45.1)	214 (48.2)	723 (49.5)	0.564	0.47 0.94 (0.79-1.12)	0.462 0.93 (0.78-1.12)
Controls	996	28 (54.9)	230 (51.8)	738 (50.5)	0.85 (0.49-1.48)		
Dead 28 days	57	4 (17.4)	8 (3.7)	45 (6.2)	0.042	0.88 1.04 (0.61-1.78)	0.874 1.05 (0.61-1.80)
Alive 28 days	903	19 (82.6)	206 (96.3)	678 (93.8)	3.51 (1.15-10.7)		
Dead 90 days	76	4 (17.4)	11 (5.1)	61 (8.4)	0.101	0.70 0.91 (0.56-1.48)	0.696 0.91 (0.55-1.49)
Alive 90 days	884	19 (82.6)	203 (94.9)	662 (91.6)	2.53 (0.84-7.63)		
ARDS	64	2 (8.7)	13 (6.1)	49 (6.8)	0.662	0.93 0.98 (0.58-1.54)	0.929 0.98 (0.58-1.66)
No ARDS	896	21 (91.3)	201 (93.9)	674 (93.2)	1.34 (0.31-5.86)		
SS/SSh	313	14 (60.9)	66 (30.8)	233 (32.2)	0.003*	0.2 1.19 (0.91-	0.189 1.20 (0.91-1.58)
No SS/SSh	647	9 (39.1)	148 (69.2)	490 (67.8)	3.32 (1.42-7.76)		

	N						
						1.56)	
Sepsis	765	22 (95.7)	165 (77.1)	578 (79.9)	0.025	0.77	0.764
No sepsis	195	1 (4.3)	49 (22.9)	145 (20.1)	5.74 (0.77-42.9)	1.05 (0.76-1.45)	1.05 (0.76-1.46)
ICU	338	9 (39.1)	68 (31.8)	261 (36.1)	0.690	0.45	0.439
No ICU	622	14 (60.9)	146 (68.2)	462 (63.9)	1.19 (0.51-2.77)	0.90 (0.69-1.18)	0.90 (0.68-1.18)
ICU dead 28 d	44	2 (22.2)	5 (7.4)	37 (14.2)	0.331	0.46	0.451
ICU alive 28 d	224	7 (77.8)	63 (92.6)	224 (85.8)	1.95 (0.39-9.71)	0.77 (0.38-1.56)	0.76 (0.36-1.57)
ICU dead 90 d	62	2 (22.2)	8 (11.8)	52 (19.9)	0.672	0.27	0.260
ICU alive 90 d	276	7 (77.8)	60 (88.2)	209 (80.1)	1.28 (0.26-6.32)	0.71 (0.38-1.33)	0.69 (0.36-1.32)

Data are number of patients with percentage in parentheses.

N, number of patients; CAP: community-acquired pneumonia; ARDS, acute respiratory distress syndrome; SS/SSh: Severe Sepsis /Septic shock; ICU, intensive care unit; ICU dead 28 d: patients admitted to the ICU who died at 28 days; ICU alive 28 d: patients admitted to the ICU who survived; ICU dead 90 d: patients admitted to the ICU who died at 90 days; ICU alive 90 d: patients admitted to the ICU who survived.

*p value for the bivariate comparison calculated with the χ^2 test. OR (95% CI), Odds ratio (95% confidence interval).

After adjustment for age, sex, comorbidites and admitting hospital, the rs62375529*FER* variant remains significantly associated with severe sepsis risk (OR=5.17; 95% CI 1.963-13.68, p=0.001), *p* value for the multivariate analysis calculated with binary logistic regression.

Bivariate and multivariate analyses were performed using the SPSS (version 15.0) (SPSS, Inc, Chicago, Ill, USA). The mean age of the patients and controls was 61.8 ± 17.7 and 44.3 ± 19.3 respectively; 620 (66%) patients and 435 controls (52%) were males. Genotype distribution of both SNPs did not differ significantly under conditions of Hardy-Weinberg equilibrium in the control group (p= 0.444 for rs4957796, p=0.746 for rs62375529).